Jw Creagene Inc.

Sungkyunkwan University

Yong-Soo Bae

Young-Mok Kim

Seung-Soo Han

Yoon Sung Lee

Yoon Young Lee

So-Yeon Kim

Jun-Eui Park

Yun-Ju Woo

Jin-Ah Jang

Hye-Won Kang

Seo-Hee Ahn

Se Eun Byeon

Selim Ahmed

Yideul Jeong

The present invention relates to a method for preparing a dendritic cell, a dendritic cell prepared thereby and a use thereof, and more specifically, to a method for preparing a dendritic cell, including: treating a dendritic cell at a maturation stage rather than at an immature stage with an antigen bound to a peptide having a cell membrane permeability to prepare a dendritic cell with improved antigen-presenting ability, a dendritic cell prepared by the method, and an immunotherapeutic agent thereof, a use for anti-tumor vaccines, or a pharmaceutical composition for treating tumors, containing the same.

Method for preparing dendritic cell, dendritic cell prepared thereby, and use thereof

The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.

Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same

The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1&#x3b2; (IL-1&#x3b2;), Interleukin-6 (IL-6), Tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), Interferon-&#x3b3; (IFN-&#x3b3;), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.

Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same

Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer.

Pharmaceutical composition for preventing or treating cancers comprising dendritic cells with Dab2 gene silenced

Growing community of inventors

Gyeonggi-do, South Korea

Yong-Soo Bae